Thrombosis News and Research

Latest Thrombosis News and Research

FDA accepts Regado Biosciences' IND application for REG2

Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.

13 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Chest radiography highly predictive of pulmonary hypertension

Chest radiography is very accurate for predicting pulmonary hypertension, report researchers.

3 Feb 2014

Research helps identify stroke patients at risk for mortality and treatments to reduce death rate

For patients who have experienced a large stroke that cuts off blood supply to a large part of the brain, the use of standardized medical management protocol and surgery to decompress swelling can improve life expectancy, Mayo Clinic researchers found in a recent study.

28 Jan 2014

Use of standardized medical management protocol and surgery can improve life expectancy

28 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Clinical rule stratifies CAP patients’ cardiac risk

Researchers have generated and validated a clinical rule that accurately stratifies patients hospitalized for community acquired pneumonia according to their risk for cardiac complications.

20 Jan 2014

Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

As co-ordinator of the European project ‘ReBioStent’, Ceram, the international materials technology company, is pleased to announce that the project, to develop new biomaterials and new arterial stents, has been awarded Euro 5.874M by the European Union.

20 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

15 Jan 2014

T2HemoStat detection of novel clot behavior could direct therapeutic choices for stroke, heart attack victims

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.

10 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Proteon Therapeutics, Inc., a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, today announced that its lead product, PRT-201, has received orphan drug designation in the European Union for the prevention of arteriovenous access dysfunction in hemodialysis patients.

9 Jan 2014

Study shows that anticoagulant medicine appears to protect patients against stroke

Heart palpitations. Shortness of breath. Tiredness. More and more people can recognise the symptoms of atrial fibrillation, which is one of the most common types of heart disease.

9 Jan 2014

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency.

7 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Autoimmune clue to narcolepsy

Researchers have identified immune cells in patients with narcolepsy that react against hypocretin, the lack of which causes the disorder.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application for its oral, once-daily direct factor Xa-inhibitor LIXIANA® (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry of Health, Labour and Welfare. Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation and symptomatic venous thromboembolism.

19 Dec 2013

Low vitamin D a consequence not a cause of ill health

Low vitamin D status is a marker of ill health rather than an underlying cause of disease, say the authors of a systematic review published in The Lancet Diabetes and Endocrinology.

16 Dec 2013

Thrombosis News and Research

Latest Thrombosis News and Research

FDA accepts Regado Biosciences' IND application for REG2

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Chest radiography highly predictive of pulmonary hypertension

Research helps identify stroke patients at risk for mortality and treatments to reduce death rate

Use of standardized medical management protocol and surgery can improve life expectancy

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Clinical rule stratifies CAP patients’ cardiac risk

Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

T2HemoStat detection of novel clot behavior could direct therapeutic choices for stroke, heart attack victims

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Study shows that anticoagulant medicine appears to protect patients against stroke

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Autoimmune clue to narcolepsy

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Daiichi Sankyo submits LIXIANA supplemental NDA for review in Japan

Low vitamin D a consequence not a cause of ill health

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in